Press coverage about Akers Biosciences (NASDAQ:AKER) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akers Biosciences earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.4659418948174 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Akers Biosciences’ UK Distributor Secures New Channel For Rapid Alcohol Breathalyzer (thestreet.com)
- Akers Biosciences : rsquo; UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer (4-traders.com)
- Akers Bio expects sales of its ‘morning after’ alcohol breath test to ramp up as distributor secures major new channel partner (proactiveinvestors.co.uk)
- BRIEF-Akers Biosciences – Accutest Solutions secured new channel partner for sales (reuters.com)
- Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer (finance.yahoo.com)
Shares of Akers Biosciences (AKER) opened at $0.79 on Wednesday. Akers Biosciences has a one year low of $0.68 and a one year high of $3.30.
Akers Biosciences (NASDAQ:AKER) last announced its earnings results on Monday, August 14th. The medical instruments supplier reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.04). The company had revenue of $1.20 million during the quarter. Akers Biosciences had a negative net margin of 89.49% and a negative return on equity of 59.94%.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/15/akers-biosciences-aker-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Akers Biosciences Company Profile
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.